Enhancer of zeste homolog 2 (EZH2) is enzymatic catalytic subunit of polycomb repressive
complex 2 (PRC2) that can alter downstream target genes expression by trimethylation of …

Next-generation genomic sequencing has identified multiple novel molecular alterations in
cancer. Since the identification of DNA methylation and histone modification, it has become …

Canonically, EZH2 serves as the catalytic subunit of PRC2, which mediates H3K27me3
deposition and transcriptional repression. Here, we report that in acute leukaemias, EZH2 …

The persistence of cancer cells resistant to therapy remains a major clinical challenge. In
triple-negative breast cancer, resistance to chemotherapy results in the highest recurrence …

Addition of chemical tags on the DNA and modification of histone proteins impart a distinct
feature on chromatin architecture. With the advancement in scientific research, the key …

Protein lysine methylation is a crucial post-translational modification that regulates the
functions of both histone and non-histone proteins. Deregulation of the enzymes or 'writers' …

Recent genomic studies have resulted in an emerging understanding of the role of
chromatin regulators in the development of cancer. EZH2, a histone methyl transferase …

Over the past decade, remarkable advances have been witnessed in the development of
small-molecule probes. These molecular tools have been widely applied for interrogating …

Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain tumor that is located in the
pons and primarily affects children. Nearly 80% of DIPGs harbor mutations in histone H3 …

Enhancer of zeste homologue 2 (EZH2), the catalytic subunit of Polycomb repressive
complex 2 (PRC2), has attracted broad research attention in the past few years because of …